NISA INVESTMENT ADVISORS, LLC - BLUEPRINT MEDICINES CORP ownership

BLUEPRINT MEDICINES CORP's ticker is BPMC and the CUSIP is 09627Y109. A total of 237 filers reported holding BLUEPRINT MEDICINES CORP in Q2 2020. The put-call ratio across all filers is 1.19 and the average weighting 0.3%.

Quarter-by-quarter ownership
NISA INVESTMENT ADVISORS, LLC ownership history of BLUEPRINT MEDICINES CORP
ValueSharesWeighting
Q3 2023$101,947
-20.5%
2,0300.0%0.00%0.0%
Q2 2023$128,296
+178088.9%
2,030
+26.5%
0.00%0.0%
Q1 2023$72
+166.7%
1,605
+158.0%
0.00%
Q4 2022$27
-99.9%
622
-1.4%
0.00%
Q3 2022$33,000
-5.7%
631
-7.7%
0.00%
Q2 2022$35,000
+20.7%
684
+50.7%
0.00%
Q1 2022$29,000
-88.8%
454
-86.5%
0.00%
-100.0%
Q4 2021$260,000
+7.9%
3,368
+43.7%
0.00%
+100.0%
Q3 2021$241,000
-34.2%
2,343
-43.6%
0.00%
-50.0%
Q2 2021$366,000
-9.4%
4,1560.0%0.00%
-33.3%
Q1 2021$404,000
-13.3%
4,1560.0%0.00%0.0%
Q4 2020$466,000
+175.7%
4,156
+128.4%
0.00%
+200.0%
Q3 2020$169,000
+369.4%
1,820
+295.7%
0.00%
Q2 2020$36,000
+63.6%
460
+24.3%
0.00%
Q1 2020$22,000
-40.5%
370
-19.6%
0.00%
Q4 2019$37,000
+76.2%
460
+64.3%
0.00%
Q3 2019$21,000
+10.5%
280
+40.0%
0.00%
Q2 2019$19,000
+18.8%
2000.0%0.00%
Q1 2019$16,000
+45.5%
2000.0%0.00%
Q4 2018$11,000
-31.2%
2000.0%0.00%
Q3 2018$16,000
+23.1%
2000.0%0.00%
Q2 2018$13,000
-27.8%
2000.0%0.00%
Q1 2018$18,000
-21.7%
200
-33.3%
0.00%
Q4 2017$23,000
+9.5%
3000.0%0.00%
Q3 2017$21,0003000.00%
Other shareholders
BLUEPRINT MEDICINES CORP shareholders Q2 2020
NameSharesValueWeighting ↓
Aquilo Capital Management, LLC 423,012$41,129,0007.43%
Eagle Health Investments LP 133,163$12,947,0005.08%
DAFNA Capital Management LLC 207,911$20,215,0004.80%
Casdin Capital, LLC 1,550,000$150,707,0004.49%
SIB LLC 65,151$6,335,0003.72%
CADIAN CAPITAL MANAGEMENT, LP 913,702$88,839,0003.29%
Integral Health Asset Management, LLC 117,500$11,425,0003.26%
Rock Springs Capital Management LP 746,732$72,605,0001.58%
Avidity Partners Management LP 546,000$53,088,0001.47%
Zebra Capital Management LLC 12,698$1,235,0001.36%
View complete list of BLUEPRINT MEDICINES CORP shareholders